ZymoGenetics, Inc. Earns Milestone Payment for RECOTHROM(R) European Filing

SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that it will receive a $5 million milestone payment from Bayer HealthCare, which was triggered by the submission of the Marketing Authorization Application to the European Medicines Agency (EMEA) for approval to market RECOTHROM® Thrombin, topical (Recombinant). Bayer filed with the EMEA for authorization to market RECOTHROM as a topical aid to control surgical bleeding. RECOTHROM received United States Food and Drug Administration approval in January 2008.